NO20091748L - Mikroorganismer eller fraksjoner derav, istand til aktivering avcellulaer immunitet mot karbohydrater - Google Patents

Mikroorganismer eller fraksjoner derav, istand til aktivering avcellulaer immunitet mot karbohydrater

Info

Publication number
NO20091748L
NO20091748L NO20091748A NO20091748A NO20091748L NO 20091748 L NO20091748 L NO 20091748L NO 20091748 A NO20091748 A NO 20091748A NO 20091748 A NO20091748 A NO 20091748A NO 20091748 L NO20091748 L NO 20091748L
Authority
NO
Norway
Prior art keywords
carbohydrates
microorganisms
fractions
cellular immunity
activating cellular
Prior art date
Application number
NO20091748A
Other languages
English (en)
Norwegian (no)
Inventor
Steffen Goletz
Philippe Ulsemer
Anja Loffler
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39200183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091748(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of NO20091748L publication Critical patent/NO20091748L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
NO20091748A 2006-11-10 2009-05-04 Mikroorganismer eller fraksjoner derav, istand til aktivering avcellulaer immunitet mot karbohydrater NO20091748L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090208.7A EP1920781B1 (en) 2006-11-10 2006-11-10 Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
EP06090209A EP1920782A1 (en) 2006-11-10 2006-11-10 Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
PCT/EP2007/009766 WO2008055703A2 (en) 2006-11-10 2007-11-12 Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates

Publications (1)

Publication Number Publication Date
NO20091748L true NO20091748L (no) 2009-07-14

Family

ID=39200183

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091748A NO20091748L (no) 2006-11-10 2009-05-04 Mikroorganismer eller fraksjoner derav, istand til aktivering avcellulaer immunitet mot karbohydrater

Country Status (18)

Country Link
US (2) US8592165B2 (ru)
EP (4) EP1920781B1 (ru)
JP (4) JP5771355B2 (ru)
KR (2) KR20150054014A (ru)
CN (1) CN101573138B (ru)
AU (2) AU2007316819B2 (ru)
BR (2) BRPI0719005A2 (ru)
CA (2) CA2668603A1 (ru)
EA (1) EA025395B1 (ru)
ES (1) ES2715045T3 (ru)
HK (1) HK1136219A1 (ru)
IL (2) IL198567A0 (ru)
MX (1) MX2009005004A (ru)
NO (1) NO20091748L (ru)
NZ (1) NZ577559A (ru)
PL (1) PL1920781T3 (ru)
RU (1) RU2460074C2 (ru)
WO (2) WO2008055702A1 (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101603632B1 (ko) 2006-09-10 2016-03-16 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US8741365B2 (en) 2008-05-13 2014-06-03 Glycotope Gmbh Fermentation process
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
US20120190025A1 (en) * 2009-07-27 2012-07-26 Angelia Denene Blackwood Enterococcus and fecal bacteroides for rapid water quality assessment
GB2475226A (en) 2009-11-03 2011-05-18 Genetic Analysis As Universal Prokaryote 16S ribosome PCR primer pair
JP2013527240A (ja) * 2010-06-01 2013-06-27 モーア リサーチ エンタープライズイズ エルエルシー バクテロイデスからの細胞成分、その組成物、およびバクテロイデスまたはその細胞成分を使用した治療方法
EP2646567A4 (en) * 2010-10-04 2014-03-26 British Columbia Cancer Agency DETECTION OF FUSOBACTERIUM IN A GASTROINTESTINAL SAMPLE TO DIAGNOSE GASTROINTESTINAL CANCER
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
BR112014004065A2 (pt) * 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
CA2844542A1 (en) * 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms of the species bacteroides xylanisolvens
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DK2877590T3 (en) * 2012-06-26 2016-07-04 Centre Hospitalier Regional Univ Lille Method for in vitro diagnosis of invasive fungal infection by MALDI-TOF mass spectrometry
CN102813916B (zh) * 2012-09-05 2015-03-11 北京希普生国际生物医学研究院 一种快速获取树突状细胞疫苗的制备方法及其应用
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP2818056A1 (en) * 2013-06-25 2014-12-31 Biosearch S.A. Probiotic bacteria comprising metals, metal nanoparticles and uses thereof
US11155801B2 (en) * 2013-08-06 2021-10-26 Trustees Of Dartmouth College Unglycosylated lysostaphin variant protein
RU2016138744A (ru) 2014-04-10 2018-05-11 Оби Фарма Инк. Антитела, фармацевтические композиции и их применения
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN104546932A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546933A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
JP6427278B2 (ja) * 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ ｐｉｒｉｎポリペプチド及び免疫モジュレーション
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
EP3250215A4 (en) 2015-01-29 2018-08-08 Oxyrase, Inc. Methods for inhibiting tumor growth
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
SI3360559T1 (sl) 2015-06-15 2020-02-28 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
CN114984057A (zh) 2015-06-15 2022-09-02 4D制药研究有限公司 包含细菌菌株的组合物
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3209310B1 (en) 2015-11-20 2018-01-31 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
NZ745678A (en) 2016-03-04 2019-03-29 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
SG11201811227QA (en) 2016-07-01 2019-01-30 Evolve Biosystems Inc Method for facilitating maturation of the mammalian immune system
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
AU2018272291A1 (en) 2017-05-22 2020-01-16 4D Pharma Research Limited Compositions comprising bacterial strains
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
CN111107859B (zh) 2017-06-14 2022-04-29 4D制药研究有限公司 包含细菌菌株的组合物
ES2917415T3 (es) 2017-06-14 2022-07-08 4D Pharma Res Ltd Composiciones que comprenden una cepa bacteriana
HUE052319T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
BR112019028301A2 (pt) 2017-07-05 2020-07-14 Evelo Biosciences, Inc. composições e métodos para tratar câncer com o uso de bifidobacterium animalis ssp. lactis
TWI842710B (zh) * 2018-05-11 2024-05-21 台灣浩鼎生技股份有限公司 預測人體免疫反應的方法
TWI825098B (zh) 2018-05-18 2023-12-11 德商葛萊高托普公司 抗ｍｕｃ１抗體
CA3146738A1 (en) * 2019-07-18 2021-01-21 Synthetic Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4672316A (en) 1983-08-19 1987-06-09 Werkzeugmaschinenfabrik Oerlikon-Buhrle Ag Method for calibrating a muzzle velocity measuring device
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
EP0433299B1 (en) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Treatment of gastro-intestinal disorders
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
EP0573551B1 (en) 1991-02-27 2003-05-21 Micromet AG Serine-rich peptide linkers
AU683413B2 (en) 1992-04-13 1997-11-13 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
US7137011B1 (en) 1993-09-01 2006-11-14 Sandisk Corporation Removable mother/daughter peripheral card
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP2660175B2 (ja) * 1994-10-19 1997-10-08 北海道 キクイモ由来のレクチンおよびその分離精製法
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
CA2213775C (en) * 1995-12-27 2001-02-27 Ngk Insulators, Ltd. Cancer metastasis inhibitor containing a streptococcus agalactiae ia type or ib type surface polysaccharide as a main ingredient
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
EP1987845B1 (en) 1997-11-20 2012-03-21 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ES2488819T3 (es) * 1998-02-20 2014-08-29 Genentech, Inc. Inhibidores de la activación del complemento
JP2000028599A (ja) * 1998-04-15 2000-01-28 Ebara Corp Ｄ―マンノ―ス識別アフィニティ―担体とその使用方法
AU3508300A (en) 1999-03-02 2000-09-21 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
JP2003510334A (ja) 1999-09-30 2003-03-18 コリクサ コーポレイション 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
EP1458242A4 (en) * 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
US20050042714A1 (en) 2001-08-17 2005-02-24 Michael Pawlita Glycoconjugates of sialic acid derivates, methods for their production and use thereof
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
CN1201817C (zh) * 2001-11-09 2005-05-18 北京大学肝病研究所 一种治疗肝癌的肿瘤ct抗原免疫诱导剂及其制备方法
EP1451217A4 (en) * 2001-11-20 2005-10-12 Atgen Co Ltd NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
AU2003266236A1 (en) * 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
DE60334382D1 (de) 2002-08-16 2010-11-11 Glycotope Gmbh Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
AU2003275990A1 (en) * 2002-09-26 2004-04-19 Novartis Ag Tcell mediator/modulator assay based upon tcell restricted transgenic mouse
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
EP1604016B1 (en) * 2003-02-27 2009-01-14 NorthWest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
GB0315991D0 (en) 2003-07-08 2003-08-13 Dakocytomation Denmark As Standard
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ES2425475T3 (es) 2003-08-18 2013-10-15 Glycotope Gmbh Líneas de células tumorales NM-F9 (DSM ACC2606) y NM-D4 (DSM ACC2605), usos de las mismas
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
WO2005080585A1 (en) 2004-02-13 2005-09-01 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
US20080193440A1 (en) * 2004-07-01 2008-08-14 Kobenhavns Universitet Method For Multiple Sclerosis Treatment and Prophylaxis By Treatment of Leptospira Infection
US7374755B2 (en) * 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
CN101262760A (zh) * 2005-08-01 2008-09-10 加拿大农业和农业食品部 包含高油酸、低亚麻酸油的低纤维黄色油菜种子
KR101603632B1 (ko) * 2006-09-10 2016-03-16 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
US8741365B2 (en) * 2008-05-13 2014-06-03 Glycotope Gmbh Fermentation process
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
BR112014004065A2 (pt) * 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor

Also Published As

Publication number Publication date
CA2668704A1 (en) 2008-05-15
EA200970471A1 (ru) 2009-12-30
WO2008055703A9 (en) 2008-10-02
JP2015134813A (ja) 2015-07-27
EP2101814A1 (en) 2009-09-23
RU2460074C2 (ru) 2012-08-27
WO2008055703A2 (en) 2008-05-15
US20100303837A1 (en) 2010-12-02
JP5771355B2 (ja) 2015-08-26
AU2007316820B2 (en) 2013-09-05
EP2099480A2 (en) 2009-09-16
RU2009122204A (ru) 2010-12-20
IL198626A0 (en) 2011-08-01
US9494587B2 (en) 2016-11-15
CN101573138A (zh) 2009-11-04
CN101573138B (zh) 2015-04-29
HK1136219A1 (en) 2010-06-25
EP2099480B2 (en) 2024-06-12
EP1920781B1 (en) 2015-03-04
WO2008055702A1 (en) 2008-05-15
EP1920782A1 (en) 2008-05-14
CA2668603A1 (en) 2008-05-15
JP2010508834A (ja) 2010-03-25
EA025395B1 (ru) 2016-12-30
EP1920781A1 (en) 2008-05-14
BRPI0719005A2 (pt) 2013-12-17
BRPI0718796A2 (pt) 2014-02-18
ES2715045T3 (es) 2019-05-31
JP2015133979A (ja) 2015-07-27
KR20090080554A (ko) 2009-07-24
US8592165B2 (en) 2013-11-26
IL198626A (en) 2015-05-31
NZ577559A (en) 2012-01-12
JP2010508833A (ja) 2010-03-25
AU2007316819B2 (en) 2013-08-22
PL1920781T3 (pl) 2015-06-30
IL198567A0 (en) 2011-08-01
MX2009005004A (es) 2009-07-31
AU2007316819A1 (en) 2008-05-15
US20100158952A1 (en) 2010-06-24
WO2008055703A3 (en) 2008-12-04
AU2007316820A1 (en) 2008-05-15
KR20150054014A (ko) 2015-05-19
EP2099480B1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
NO20091748L (no) Mikroorganismer eller fraksjoner derav, istand til aktivering avcellulaer immunitet mot karbohydrater
NO20083153L (no) Kjemiske forbindelser
WO2005084305A3 (en) Flavonoids
GB0619291D0 (en) Altered antibodies
NO20080622L (no) Disykloalkylurea-glukokinase aktivatorer
BRPI0508628A (pt) conjugados de hidroxialquil amido e uma proteìna
WO2007095638A3 (en) Boron-containing small molecules as anti-inflammatory agents
WO2007047408A3 (en) Promac signature application
NO20092023L (no) Oligoribonuleotider og anvendelser derav
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
EP1801213A3 (en) Polymerase
WO2005105785A3 (en) Indole derivatives for treatment of obesity
ATE486297T1 (de) Mehrstufige schicht
TW200716525A (en) Process for preparation of sulfamide derivatives
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
TW200700064A (en) Novel compounds
WO2006050341A3 (en) Modified streptococcal polysaccharides and uses thereof
WO2007008583A3 (en) Improved protein expression comparison assay results and applications
WO2008066784A3 (en) Expression of foxp3 by cancer cells
MX2009012612A (es) Purinonas e inhibidores 1h-imidazopiridinonas como pkc-theta.
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
NO20072290L (no) Organiske forbindelser.
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
TW200624479A (en) Film forming material and preparation of surface relief and optically anisotropic structures by irradiating a film of the said material

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application